Skip to ContentSkip to Navigation
About usNews and EventsNews articles

Groningen researchers crucial in development of new flu vaccine

25 October 2013

A team of researchers from the University of Groningen is going to head a major European project to develop new flu vaccines. The project will concentrate on developing vaccines that can offer broad protection against the flu virus.

The Groningen research team is headed by Prof. H.W. Frijlink (research leader), Prof. A.L.W. Huckriede and Prof. E. Hak. The project, entitled Universal Influenza Vaccine Secured, will be implemented by a consortium of twelve partners from seven European countries: four businesses, five national health institutes and three universities.

Virus variants

Because the flu virus is constantly mutating (changes occur to the genome), annual vaccination campaigns need to be held in order to achieve adequate protection against it. Reserves of the vaccine to be used in the event of a pandemic (for example Mexican or Spanish flu) cannot be built up either. After all, you never know which variant of the virus will cause the pandemic.

The new project will investigate and develop new types of vaccine that will protect against all variants of the flu virus. This will remove the necessity to be vaccinated every year and reserves can be built up to be used in the event of a pandemic.

Protection

In addition to a promising variant of the current vaccine that can be administered in powder form via inhalation and thus offers wider protection, the project will also investigate two peptide vaccines, a DNA vaccine and a vaccine that concentrates on the M2 protein. Specific new tests will be developed for all these vaccines, with a high predictive value for the protection that the vaccine offers to humans. Studies on humans will be conducted to compare the various vaccines with each other.

The University of Groningen has developed a basic technology that can stabilize powder vaccines. This means that the current flu vaccine can be stored for ten years at room temperature without deteriorating; normal vaccine can only be stored for a year in a fridge. Applying this technology to the new vaccines will also be investigated, so that reserves can be built up for a possible pandemic.

Note for the press

Further information: Prof. H.W. Frijlink

Last modified:15 September 2017 3.32 p.m.
printView this page in: Nederlands

More news

  • 24 May 2019

    Four UG researchers win Vidi grants

    The Netherlands Organisation for Scientific Research (NWO) has awarded an EUR 800,000 Vidi grant each to 86 experienced researchers. Four of these conduct their research at just one faculty at the University of Groningen (UG): the Faculty of Science...

  • 24 May 2019

    First edition of Top HR Leadership Programme successfully completed

    The University of Groningen Business School (UGBS) and the In the LEAD centre of expertise at the University of Groningen are looking back on a successful first edition of the Top HR Leadership programme. On 21 May, eight top HR professionals with different...

  • 22 May 2019

    The North of the Netherlands goes down under during Solar Challenge

    Students of Hanze University of Applied Sciences (UAS), University of Groningen and Noorderpoort will be competing in the Bridgestone World Solar Challenge in Australia for the first time, with their own uniquely built and designed solar car called...